Exploring Potential of RPPA Technique in Oral Cancer Biomarker Discovery Research

2019 ◽  
pp. 269-292 ◽  
Author(s):  
Neera Singh ◽  
Sanghamitra Pati
Keyword(s):  
Oral Cancer ◽  
Biomarker Discovery ◽  
Cancer Biomarker ◽  
Discovery Research

scholarly journals Salivary Proteomics for Oral Cancer Biomarker Discovery

2008 ◽  
Vol 14 (19) ◽  
pp. 6246-6252 ◽  
Author(s):  
Shen Hu ◽  
Martha Arellano ◽  
Pinmanee Boontheung ◽  
Jianghua Wang ◽  
Hui Zhou ◽  
...  
Keyword(s):  
Oral Cancer ◽  
Biomarker Discovery ◽  
Cancer Biomarker

scholarly journals Evaluating the potential of a novel oral lesion exudate collection method coupled with mass spectrometry-based proteomics for oral cancer biomarker discovery

2011 ◽  
Vol 8 (1) ◽  
pp. 13 ◽  
Author(s):  
Joel A Kooren ◽  
Nelson L Rhodus ◽  
Chuanning Tang ◽  
Pratik D Jagtap ◽  
Bryan J Horrigan ◽  
...  
Keyword(s):  
Mass Spectrometry ◽  
Oral Cancer ◽  
Biomarker Discovery ◽  
Oral Lesion ◽  
Cancer Biomarker ◽  
Collection Method

Exosomal microRNAs as Potentially Useful Tools in Cancer Biomarker Discovery

2012 ◽  
Vol 2 (3) ◽  
pp. 219-226
Author(s):  
Ryan Navarro ◽  
Narayan Shivapurkar
Keyword(s):  
Biomarker Discovery ◽  
Cancer Biomarker

Bayesian Item Response Theory for Cancer Biomarker Discovery

2019 ◽  
pp. 355-404
Author(s):  
Katabathula Ramachandra Murthy ◽  
Salendra Singh ◽  
David Tuck ◽  
Vinay Varadan
Keyword(s):  
Item Response Theory ◽  
Item Response ◽  
Biomarker Discovery ◽  
Cancer Biomarker ◽  
Response Theory

A peptide-centric approach to breast cancer biomarker discovery utilizing label-free multiple reaction monitoring mass spectrometry

2008 ◽  
Vol 3 (1) ◽  
pp. 78-82 ◽  
Author(s):  
Gergana Metodieva ◽  
Christina Greenwood ◽  
Louise Alldridge ◽  
Paul Sauven ◽  
Metodi Metodiev
Keyword(s):  
Breast Cancer ◽  
Mass Spectrometry ◽  
Biomarker Discovery ◽  
Multiple Reaction Monitoring ◽  
Cancer Biomarker ◽  
Reaction Monitoring ◽  
Label Free

scholarly journals Morph-X-Select: Morphology-based tissue aptamer selection for ovarian cancer biomarker discovery

BioTechniques ◽  
2016 ◽  
Vol 61 (5) ◽  
Author(s):  
Hongyu Wang ◽  
Xin Li ◽  
David E. Volk ◽  
Ganesh L.-R. Lokesh ◽  
Miguel-Angel Elizondo-Riojas ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Biomarker Discovery ◽  
Cancer Biomarker ◽  
Aptamer Selection ◽  
Selection For

scholarly journals Whole Blood Holding Time Prior to Plasma Processing Alters microRNA Expression Profile

2022 ◽  
Vol 12 ◽  
Author(s):  
Sung Hye Kim ◽  
David A. MacIntyre ◽  
Lynne Sykes ◽  
Maria Arianoglou ◽  
Phillip R. Bennett ◽  
...  
Keyword(s):  
Mirna Expression ◽  
Whole Blood ◽  
Biomarker Discovery ◽  
Expression Profiles ◽  
Holding Time ◽  
Circulating Mirnas ◽  
Sample Collection ◽  
Aberrant Expression ◽  
Discovery Research ◽  
Mirna Expression Profiles

MicroRNAs (miRNAs) can exhibit aberrant expression under different physiological and pathological conditions. Therefore, differentially expressed circulating miRNAs have been a focus of biomarker discovery research. However, the use of circulating miRNAs comes with challenges which may hinder the reliability for their clinical application. These include varied sample collection protocols, storage times/conditions, sample processing and analysis methods. This study focused on examining the effect of whole blood holding time on the stability of plasma miRNA expression profiles. Whole blood samples were collected from healthy pregnant women and were held at 4°C for 30 min, 2 h, 6 h or 24 h prior to processing for plasma isolation. Plasma RNA was extracted and the expression of 179 miRNAs were analyzed. Unsupervised principal component analysis demonstrated that whole blood holding time was a major source of variation in miRNA expression profiles with 53 of 179 miRNAs showing significant changes in expression. Levels of specific miRNAs previously reported to be associated with pregnancy-associated complications such as hsa-miR-150-5p, hsa-miR-191-5p, and hsa-miR-29a-3p, as well as commonly used endogenous miRNA controls, hsa-miR-16-5p, hsa-miR-25-3p, and hsa-miR-223-3p were significantly altered with increase in blood holding time. Current protocols for plasma-based miRNA profiling for diagnostics describe major differences in whole blood holding periods ranging from immediately after collection to 26 h after. Our results demonstrate holding time can have dramatic effects on analytical reliability and reproducibility. This highlights the importance of standardization of blood holding time prior to processing for plasma in order to minimize introduction of non-biological variance in miRNA profiles.

Sign in / Sign up

Export Citation Format

Share Document